Recent data from a pre-specified analysis of the SELECT trial show a beneficial effect of the glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide on kidney outcomes in patients with cardiovascular disease and overweight or obesity without diabetes. These findings were presented at the 61st European Renal Association Congress in Stockholm.

The SELECT trial, which included 17,604 participants with cardiovascular disease and BMI ≥27 kg/m2 without diabetes, showed that once-weekly treatment with subcutaneous semaglutide (2.4 mg) was associated with a 20% reduction in major cardiovascular events compared with placebo.